The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneously (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).
Diagnosis of MS
RMS and PPMS participants diagnosed according to the McDonald criteria of 2017 or revised McDonald criteria 2024
First treatment during the course of MS therapy with ocrelizumab SC according to the local prescribing information, regardless of the reason for starting treatment with ocrelizumab
Participation in interventional studies investigating DMTs for MS
Prior or simultaneous participation in CONFIDENCE or MoOzaRt (ISRCTN55332718) non interventional study (NIS) at the same study site
Prior treatment with rituximab (MabThera®) or ublituximab (Briumvi®)
Severe psychiatric disability